Researchers from Moscow-based Gamaleya institute, an offshoot of the Russian Ministry of Health, published detailed phase 1/2 results of their COVID-19 vaccine in the Lancet. If true (remember that we are talking about Russia), these results imply that their vaccine is both effective and has a tolerable safety profile which would make it a strong contender in the international race to defeat COVID-19.
Since the start of the current pandemic researchers and policymakers have worried about possible mutations of SARS-CoV-2. A recent paper based on over 18 500 virus genome samples collected thus far concludes that these worries are unfounded.
Recently, the first documented case of reinfection with SARS-CoV-2 has apparently surfaced in Hong Kong. A day later, Belgium and the Netherlands also reported a reinfection each. Is it time to worry about acquired immunity and vaccine efficacy? There are three scenarios how this might turn out.
When Russian President Vladimir Putin celebrated his “Mission Accomplished” moment on August 11th with the announcement of Sputnik V, the world’s first SARS-CoV-2 vaccine, the global scientific community reacted with a mix of skepticism and condemnation. Is this warranted or a result of russophobia?
Covid19 vaccine: The companies Biontech and Pfizer developed effective antibodies in initial tests. The hope for a vaccine remains. Will it be logistically possible to distribute everything quickly?
The intuition of an experienced chart analyst contributes significantly to a correct forecast. With the help of around one million charts of shares, Erste AM trained the world’s first virtual chart analyst.
Trade war, a possible cooling of the world economy and growing uncertainties at the home market: is the Chinese dragon spinning?